Performance standards for antimicrobial susceptibility testing

The data in the interpretive tables in this supplement are valid only if the methodologies in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards are followed: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100 (ISBN 1-56238-804-5 [Print]; ISBN 1-56238-805-3 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017. The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org. M100S, 26th ed. January 2016 Replaces M100-S25 Performance Standards for Antimicrobial Susceptibility Testing Jean B. Patel, PhD, D(ABMM) Franklin R. Cockerill III, MD George M. Eliopoulos, MD Stephen G. Jenkins, PhD, D(ABMM), F(AAM) James S. Lewis II, PharmD Brandi Limbago, PhD David P. Nicolau, PharmD, FCCP, FIDSA Robin Patel, MD M ir Pow ll, MD, FRCP, FRCPath Sandra S. Richter, MD, D(ABMM) Jana M. Swenson, MMSc Maria M. Traczewski, BS, MT(ASCP) John D. Turnidge, MD Melvi P. Weinstein, MD Barbara L. Zimmer, PhD

[1]  Nalini Singh,et al.  Treatment of drug-resistant Shigella infections , 2015, Expert review of anti-infective therapy.

[2]  Julian Parkhill,et al.  Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study , 2011, The Lancet. Infectious diseases.

[3]  V. Gill,et al.  Correlation of penicillin minimum inhibitory concentrations and penicillin zone edge appearance with staphylococcal beta-lactamase production , 1981, Journal of clinical microbiology.

[4]  D. Citron,et al.  In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci. , 2005, Anaerobe.

[5]  Shigella with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men — United States, 2002–2013 , 2014, MMWR. Morbidity and mortality weekly report.

[6]  E. Goldstein,et al.  In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes , 2006, Antimicrobial Agents and Chemotherapy.

[7]  P. Nordmann,et al.  Value of the Modified Hodge Test for Detection of Emerging Carbapenemases in Enterobacteriaceae , 2011, Journal of Clinical Microbiology.

[8]  M. Valcanis,et al.  Malignant extraneural soft tissue perineurioma with striking microvascular proliferation. , 2015, Pathology.

[9]  S. Friedrich,et al.  Comparison of phenotypic methods for penicillinase detection in Staphylococcus aureus. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  W. Goessens,et al.  Case of Shigella flexneri infection with treatment failure due to azithromycin resistance in an HIV-positive patient , 2014, Infection.

[11]  M. Kaufmann,et al.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. , 2004, The Journal of antimicrobial chemotherapy.

[12]  Stephan Harbarth,et al.  Randomized, Placebo-Controlled, Double-Blind Trial To Evaluate the Efficacy of Mupirocin for Eradicating Carriage of Methicillin-Resistant Staphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.

[13]  S. Cosgrove,et al.  Kucers’ the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs, seventh edition , 2017 .

[14]  G. Kronvall Normalized Resistance Interpretation as a Tool for Establishing Epidemiological MIC Susceptibility Breakpoints , 2010, Journal of Clinical Microbiology.

[15]  G. Jacoby,et al.  Characterization of the Extended-Spectrum β-Lactamase Reference Strain, Klebsiella pneumoniae K6 (ATCC 700603), Which Produces the Novel Enzyme SHV-18 , 2000, Antimicrobial Agents and Chemotherapy.

[16]  Anna G. Green,et al.  Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000–2013 , 2016, The Journal of infectious diseases.

[17]  J. Patel,et al.  Evaluation of Methods To Identify the Klebsiella pneumoniae Carbapenemase in Enterobacteriaceae , 2007, Journal of Clinical Microbiology.

[18]  K. Bush,et al.  Effects of Inoculum and β-Lactamase Activity in AmpC- and Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates Tested by Using NCCLS ESBL Methodology , 2004, Journal of Clinical Microbiology.

[19]  P. Nordmann,et al.  Rapid Detection of Carbapenemase-producing Enterobacteriaceae , 2012, Emerging infectious diseases.

[20]  F. Sarubbi,et al.  Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus: Does Mupirocin Remain Effective? , 2003, Infection Control & Hospital Epidemiology.

[21]  C. Nord,et al.  European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  S. Chisholm,et al.  High-Level Azithromycin Resistance Occurs in Neisseria gonorrhoeae as a Result of a Single Point Mutation in the 23S rRNA Genes , 2010, Antimicrobial Agents and Chemotherapy.

[23]  J. Sherris,et al.  Antibiotic sensitivity testing. Report of an international collaborative study. , 1971, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.

[24]  L. Schouls,et al.  The Carbapenem Inactivation Method (CIM), a Simple and Low-Cost Alternative for the Carba NP Test to Assess Phenotypic Carbapenemase Activity in Gram-Negative Rods , 2015, PloS one.

[25]  S. Schrag,et al.  Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[26]  E. Goldstein,et al.  In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp , 2004, Antimicrobial Agents and Chemotherapy.

[27]  G. Horsman,et al.  Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant Neisseria gonorrhoeae in Canada from 1997 to 2014 , 2016, Journal of Clinical Microbiology.

[28]  Robin Patel,et al.  Rapid and Simultaneous Detection of Genes Encoding Klebsiella pneumoniae Carbapenemase (bla KPC) and New Delhi Metallo-β-Lactamase (bla NDM) in Gram-Negative Bacilli , 2013, Journal of Clinical Microbiology.

[29]  Samir N. Patel,et al.  Detection of carbapenemase activity in Enterobacteriaceae: comparison of the carbapenem inactivation method versus the Carba NP test. , 2016, The Journal of antimicrobial chemotherapy.

[30]  A. Gales,et al.  Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. , 2010, The Journal of antimicrobial chemotherapy.

[31]  G Kahlmeter,et al.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  A. Kiss,et al.  Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.